TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11258331

Group type: EXPERIMENTAL
Intervention: Preoperative administration of Vazaprostan‐20 into the pulmonary artery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study: 9440417

Group type: EXPERIMENTAL
Intervention: Braced intervals (HKAFO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unbraced intervals
Number of subjects: 10
Study: 8059746

Group type: EXPERIMENTAL
Intervention: Oral irrigation with automatic toothbrush (n = 16)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oral irrigation with manual toothbrushing (n = 16)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group with continued normal toothbrushing (n = 15)
Number of subjects: 47
Study: 3133716

Group type: EXPERIMENTAL
Intervention: Trazodone 150 mg nocte
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mianserin 30 mg nocte for 7 days, then 60 mg nocte for 5 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both treatments (Trazodone and Mianserin)
Number of subjects: 39
Study: 31648986

Group type: EXPERIMENTAL
Intervention: Integrated analysis of mutational, genomic, and expression profiles
Number of subjects: 223
Study: 28089385

Group type: EXPERIMENTAL
Intervention: Computer-assisted telephone interview
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interview
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (untailored invitation and FOBT kit mailing)
Number of subjects: 19
Study: 25500422

Group type: EXPERIMENTAL
Intervention: Radiation boost of 16 Gy
Number of subjects: 5318

Group type: COMPARATOR
Intervention: No radiation boost
Number of subjects: 5318
Study: 23161209

Group type: EXPERIMENTAL
Intervention: Intervention group (HIV risk reduction interventions)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Enhanced standard of care with the PMTCT protocol (Control)
Number of subjects: 239
Study: 21318637

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Diaphragmatic inspiratory resistive breathing (DR)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with diaphragmatic inspiratory resistive breathing (CE)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonexercise control (NE)
Number of subjects: 88
Study: 19645912

Group type: EXPERIMENTAL
Intervention: Vibrotactile biofeedback (BF) applied to the lateral trunk during tandem gait practice.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Practice alone (without vibrotactile biofeedback).
Number of subjects: 0
Study: 17013478

Group type: EXPERIMENTAL
Intervention: Open method (excision and healing by secondary intention)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Primary closure (primary midline suturing after excision)
Number of subjects: 77
Study: 15111846

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg once a day for 45 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15556053

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low dose aspirin (≤125 mg daily)
Number of subjects: 10
Study: 10708172

Group type: EXPERIMENTAL
Intervention: Using the pre-sedation GCS score for APACHE II and III calculations
Number of subjects: 13291

Group type: COMPARATOR
Intervention: Assuming normal GCS score for APACHE II and III calculations
Number of subjects: 13291
Study: 9105945

Group type: EXPERIMENTAL
Intervention: Self-paced tasks (visual matrix problem solving and mirror tracing)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Externally-paced tasks (with imposed work pace requirements)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Self-paced tasks (mirror tracing)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Externally-paced tasks (visual matrix task)
Number of subjects: 132
Study: 1491774

Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg single oral administration)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Ketoconazole (200 mg capsules daily for 5 days)
Number of subjects: 174
Study: 3100311

Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids (1, 4, or 8 tablets, 244 mg aluminium per tablet) taken with citric acid solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids (1, 4, or 8 tablets, 244 mg aluminium per tablet) taken with orange juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids (4 tablets) taken with water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids (1, 4, or 8 tablets) taken with water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All doses of aluminium containing antacids
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aluminium containing antacids taken with orange juice or citric acid
Number of subjects: 10
Study: 29327170

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive Movement Control
Number of subjects: 11
Study: 26814280

Group type: EXPERIMENTAL
Intervention: Daily morphine (n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Matched placebo (n=10)
Number of subjects: 21
Study: 23548501

Group type: EXPERIMENTAL
Intervention: Informational video intervention (IVI)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 185
Study: 22908326

Group type: COMPARATOR
Intervention: Anti-TNF therapy (SpA patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anti-TNF therapy (mAbs)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Etanercept (Anti-TNF therapy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Older age and mAb treatment
Number of subjects: 120
Study: 20492876

Group type: EXPERIMENTAL
Intervention: Intermittent etanercept therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous etanercept therapy
Number of subjects: 0
Study: 18639771

Group type: EXPERIMENTAL
Intervention: Ezetimibe-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 0
Study: 15817189

Group type: EXPERIMENTAL
Intervention: First-episode schizophrenia patients (n = 7)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia patients (n = 18)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal subjects (n = 24)
Number of subjects: 49
Study: 14500118

Group type: EXPERIMENTAL
Intervention: 2 Hz rTMS at 90% of the individual motor threshold (MT) applied over the right parietal cortex for 20 min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 8
Study: 10597850

Group type: EXPERIMENTAL
Intervention: Eccentric strengthening for quadriceps and hamstrings
Number of subjects: 17
Study: 8600096

Group type: EXPERIMENTAL
Intervention: AK-2123 (880 mg) with discontinuous accelerated hyperfractionated radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AK-2123 (990 mg) with discontinuous accelerated hyperfractionated radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (discontinuous accelerated hyperfractionated radiation alone)
Number of subjects: 0
Study: 1747056

Group type: EXPERIMENTAL
Intervention: Fundoplication alone (group 1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fundoplication with proximal gastric vagotomy (group 2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (group 1 and group 2)
Number of subjects: 54
Study: 6817123

Group type: EXPERIMENTAL
Intervention: Captopril after diuretic (thiazide) pretreatment
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Captopril without diuretic (thiazide) pretreatment
Number of subjects: 350
Study: 30105808

Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy (EFT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care (couple therapy other than EFT)
Number of subjects: 16
Study: 28910303

Group type: EXPERIMENTAL
Intervention: Remifentanil and midazolam
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Fentanyl and midazolam
Number of subjects: 105

Group type: COMPARATOR
Intervention: Midazolam (control group)
Number of subjects: 105
Study: 26224886

Group type: EXPERIMENTAL
Intervention: 7-day hypocaloric diet (‐500 kcal/day) low in saturated fat (<7% of energy)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Isocaloric diet with usual amount of saturated fat (10% of energy)
Number of subjects: 15
Study: 23758233

Group type: EXPERIMENTAL
Intervention: Inhaled racemic adrenaline
Number of subjects: 404

Group type: COMPARATOR
Intervention: Inhaled saline
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: On-demand inhalation
Number of subjects: 404

Group type: COMPARATOR
Intervention: Fixed-schedule inhalation
Number of subjects: 404
Study: 21821813

Group type: COMPARATOR
Intervention: Oat silage‐based diet containing starch (HS) from dry rolled corn (DRC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oat silage‐based diet containing digestible fiber (HF) from soybean hulls (SBH)
Number of subjects: 0
Study: 19249410

Group type: EXPERIMENTAL
Intervention: 1 g daily of omega‐3‐acid ethyl esters
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 1400
Study: 17288648

Group type: EXPERIMENTAL
Intervention: Exposure-based and cognitive restructuring therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (waiting-list subthreshold PTSD patients)
Number of subjects: 16
Study: 16279283

Group type: EXPERIMENTAL
Intervention: High doses of folic acid, vitamin B6, and vitamin B12
Number of subjects: 2006
Study: 12390056

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Tocopherol 400 IU daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg daily plus tocopherol 400 IU daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study: 9836032

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.6 mg.kg‐1; n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Atracurium (0.5 mg.kg‐1; n = 21)
Number of subjects: 41
Study: 7859455

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 230
Study: 2804866

Group type: EXPERIMENTAL
Intervention: Educational techniques
Number of subjects: 20

Group type: COMPARATOR
Intervention: No education (control group)
Number of subjects: 20
Study: 786022

Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ampicillin and kanamycin
Number of subjects: 54
Study: 6180050

Group type: EXPERIMENTAL
Intervention: Topical application of human fibroblast-derived (beta) interferon (HulFN-beta) at a total of 1-2 x 10(5) reference units per day, divided into 8-10 drops.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of human fibroblast-derived (beta) interferon (HulFN-beta)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid therapy or placebo containing human serum albumin, with the same administration schedule.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doses of interferon lower than 5 x 10(4) units per day
Number of subjects: 0
Study: 31730466

Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance imaging (WB-MRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 0
Study: 29362205

Group type: EXPERIMENTAL
Intervention: Video with drug risk information
Number of subjects: 2125

Group type: COMPARATOR
Intervention: Video without drug risk information
Number of subjects: 2125

Group type: EXPERIMENTAL
Intervention: Any video
Number of subjects: 2125

Group type: EXPERIMENTAL
Intervention: Video with risk information
Number of subjects: 2125

Group type: EXPERIMENTAL
Intervention: Risk vs Non-risk video conditions
Number of subjects: 2125
Study: 26577688

Group type: EXPERIMENTAL
Intervention: Karate techniques training for 14 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 25011661

Group type: EXPERIMENTAL
Intervention: Cold exposure (16°C)
Number of subjects: 12
Study: 22146002

Group type: EXPERIMENTAL
Intervention: Circum brush (CB)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Straight soft interdental brush (SB)
Number of subjects: 8
Study: 20812037

Group type: EXPERIMENTAL
Intervention: Behavioral Migraine Management+
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Behavioral Migraine Management-
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: β-blocker
Number of subjects: 176

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 176
Study: 17515403

Group type: EXPERIMENTAL
Intervention: Adjuvant anthracycline-based chemotherapy
Number of subjects: 823
Study: 12619921

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 2.5 U/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 1.0 U/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10705774

Group type: EXPERIMENTAL
Intervention: Simultaneous regression procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple-stage regression method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-channel regression method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9171127

Group type: EXPERIMENTAL
Intervention: Monopolar electrosurgery with metal cannulas
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Monopolar electrosurgery with plastic cannulas
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no electrosurgery)
Number of subjects: 19
Study: 8471372

Group type: EXPERIMENTAL
Intervention: Diclofenac 150 mg/24 h
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketoprofen 200 mg/24 h
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 3542772

Group type: EXPERIMENTAL
Intervention: Prostacyclin (5 ng/kg/min infused i.v. for 5 hrs per day during 6 consecutive days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28589894

Group type: EXPERIMENTAL
Intervention: Antenatal expressing (expressing breastmilk twice per day from 36 weeks' gestation)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Standard care (usual midwifery and obstetric care, supplemented by support from a diabetes educator)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Antenatal expressing
Number of subjects: 635

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 635
Study: 25979833

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 399

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 399
Study: 23359491

Group type: EXPERIMENTAL
Intervention: Mericitabine 1,000 mg BID plus Peg‐IFNα‐2a/RBV
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo plus Peg‐IFNα‐2a/RBV
Number of subjects: 166
Study: 22045821

Group type: EXPERIMENTAL
Intervention: Total Colonoscopy (TC)
Number of subjects: 12039

Group type: COMPARATOR
Intervention: Flexible Sigmoidoscopy (FS)
Number of subjects: 12039

Group type: COMPARATOR
Intervention: Fecal Immunochemical Test (FIT)
Number of subjects: 12039
Study: 18614144

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair of IVH
Number of subjects: 366

Group type: COMPARATOR
Intervention: Open repair of IVH
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Both laparoscopic and open repair
Number of subjects: 366
Study: 17577169

Group type: EXPERIMENTAL
Intervention: Challenging questions asked by interviewers
Number of subjects: 40
Study: 15355148

Group type: EXPERIMENTAL
Intervention: Versions of the Monty Hall dilemma involving competition that emphasizes causality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training on the collider principle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correct responses to questions about the MHD process
Number of subjects: 0
Study: 11565729

Group type: EXPERIMENTAL
Intervention: Allon thermoregulation (AT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine thermal care (RTC)
Number of subjects: 60
Study: 9093678

Group type: EXPERIMENTAL
Intervention: Head Impulse Test (HIT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Head-Shake Nystagmus (HSN)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Combination of HIT and HSN
Number of subjects: 105
Study: 8203844

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg daily for 3 days (multiple-dose administration)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg as a single dose (single-dose administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fleroxacin administered in a fed state
Number of subjects: 20
Study: 2450234

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intergroup comparison
Number of subjects: 0
Study: 31430034

Group type: EXPERIMENTAL
Intervention: Successful CTO-PCI
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Complete coronary revascularization
Number of subjects: 460

Group type: COMPARATOR
Intervention: Failed CTO-PCI
Number of subjects: 460

Group type: COMPARATOR
Intervention: Incomplete revascularization
Number of subjects: 460
Study: 31338868

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2-1.8 mg/d for 26 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28982906

Group type: COMPARATOR
Intervention: General anesthesia (GA) only
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: GA with single-injection thoracic paravertebral block (s-TPVB)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: GA with continuous thoracic paravertebral block (c-TPVB)
Number of subjects: 180
Study: 25028082

Group type: EXPERIMENTAL
Intervention: 10-g milk-LNS
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: 20-g milk-LNS
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: 20-g non-milk-LNS
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: 40-g milk-LNS
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: 40-g non-milk-LNS
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1053
Study: 23456732

Group type: EXPERIMENTAL
Intervention: ATV400 (400 mg once daily)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ATV300/r (300 mg ATV plus 100 mg ritonavir once daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: ATV400 and ATV300/r
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ATV300/r
Number of subjects: 200
Study: 20817749

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: THC (4, 6, and 6 mg, vaporized and inhaled)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Co-administration of MDMA and THC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19175841

Group type: EXPERIMENTAL
Intervention: Single-catheter approach (group 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Double-catheter approach (group 2)
Number of subjects: 110
Study: 17504540

Group type: EXPERIMENTAL
Intervention: Outpatient aftercare
Number of subjects: 4165

Group type: EXPERIMENTAL
Intervention: Residential aftercare
Number of subjects: 4165
Study: 15006036

Group type: EXPERIMENTAL
Intervention: Posttraining sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posttraining sleep deprivation
Number of subjects: 0
Study: 11890362

Group type: EXPERIMENTAL
Intervention: Ezlopitant
Number of subjects: 14
Study: 9589229

Group type: EXPERIMENTAL
Intervention: 200 ml of water with 25 g glucose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 600 ml of water with 25 g glucose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 ml of water with 25 g sucrose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 600 ml of water with 25 g sucrose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 ml of water with 25 g fructose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 600 ml of water with 25 g fructose
Number of subjects: 8
Study: 8045722

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 21
Study: 2648791

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (group 1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 36
Study: 28965137

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 200
Study: 27620550

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS) administration at a dose of 2 ng/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline (placebo) administration
Number of subjects: 21
Study: 25268019

Group type: EXPERIMENTAL
Intervention: 10 sessions of group behavioral activation (BA)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 96
Study: 23406610

Group type: EXPERIMENTAL
Intervention: Fast Track preventive intervention
Number of subjects: 891

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 891
Study: 21735655

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol hydrochloride with behavioral modification
Number of subjects: 72

Group type: COMPARATOR
Intervention: Behavioral therapy only
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 19631790

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (LNG-IUD) inserted into 20 women in Group 1 over the first 3 days of menstrual bleeding.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group 2) followed without any intervention.
Number of subjects: 40
Study: 16675080

Group type: EXPERIMENTAL
Intervention: Static stretching (five 30‐s static stretches)
Number of subjects: 0
Study: 15184349

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 240

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 240
Study: 11207994

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation therapy
Number of subjects: 68